Structure determination of the HIV‐1 envelope glycoprotein (Env) presented a number of
challenges, but several high‐resolution structures have now become available. In 2013 …

We describe the development and potential use of various designs of recombinant HIV‐1
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …

The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

Broadly neutralizing antibodies (bnAbs) to HIV delineate vaccine targets and are
prophylactic and therapeutic agents. Some of the most potent bnAbs target a quaternary …

Beginning in 2009, studies of the humoral responses of HIV‐positive individuals have led to
the identification of scores, if not hundreds, of antibodies that are both broadly reactive and …

Induction of HIV‐1 broadly neutralizing antibodies (bnAbs) to date has only been observed
in the setting of HIV‐1 infection, and then only years after HIV transmission. Thus, the …

The induction of neutralizing antibodies directed against the human immunodeficiency virus
(HIV) has received considerable attention in recent years, in part driven by renewed interest …

Induction of broadly neutralizing antibodies (bNAbs) by HIV-1 envelope glycoprotein
immunogens would be a major advance toward an effective vaccine. A critical step in this …

The generation of HIV bnAbs may be one of the greatest feats of the human immune system
and our best hope of finally creating an HIV vaccine. The striking amount of somatic …

No immunogen to date has reliably elicited broadly neutralizing antibodies to HIV in humans
or animal models. Advances in the design of immunogens that antigenically mimic the HIV …